Pilot Study on MAGE-C2 as a Potential Biomarker for Triple-Negative Breast Cancer
Table 1
Associations between MAGE-C2 expression status and clinicopathologic parameters.
Variable
MAGE-C2
value
Low expression, (%)
High expression, (%)
Total
68 (61.81)
42 (38.18)
—
Median age, years (range)
47 (22–79)
46 (27–67)
0.391
Age, (%)
0.338
≤35
14 (20.59)
12 (28.57)
>35
54 (79.41)
30 (71.43)
Tumor size, (%)
0.292
≤2 cm
19 (27.94)
8 (19.05)
>2 cm
49 (72.06)
34 (80.95)
Lymph node status, (%)
<0.001
Negative
48 (70.59)
9 (21.43)
Positive
20 (29.41)
33 (78.57)
TNM stage, (%)
<0.001
I/II
63 (92.65)
14 (33.33)
III
5 (7.35)
28 (66.67)
Differentiation, (%)
0.792
Well
7 (10.29)
6 (14.29)
Moderate/poor
61 (89.71)
36 (85.71)
Lymphovascular invasion, (%)
<0.001
Yes
4 (5.88)
21 (50.00)
No
64 (94.12)
21 (50.00)
TNM (tumor node metastasis) staging was conducted on all breast cancer patients postoperatively in accordance with the American Joint Committee on Cancer (AJCC, 7th edition). The Miller and Payne grading system was used for determining differentiation of the neoplasms.
